Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) per Mild Cognitive Impairment (MCI)

B

Research suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Dmild\u002Dcognitive\u002Dimpairment'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Research suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.

Key Study Findings

Systematic Review n=3582
Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms.
Dose: None vs: Placebo or control Outcome: Cognitive function in AD and MCI patients Effetto: None None

Popolazione: AD and MCI patients aged 50-90 (31 clinical trials)

Randomized Controlled Trial n=73 12 weeks Single-blind
Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide …
Dose: IL triamcinolone every 4 weeks + calcipotriol twice daily vs: IL triamcinolone acetonide alone Outcome: Hair density (regrowth scale) Effetto: None 0.018 (scalp subgroup at wk12)

Popolazione: Patients with scalp and beard alopecia areata (179 patches)

Review
Effects of Dietary Interventions on Cognitive Outcomes.
Dose: None vs: None Outcome: Cognitive outcomes (memory, executive function) Effetto: None None

Popolazione: Aging adults with cognitive impairment (review)

Review
Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Other
Milk Fat Globules: 2024 Updates.
Dose: None vs: None Outcome: Inflammatory markers Effetto: None None

Popolazione: None

Systematic Review
The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With …
Dose: None vs: None Outcome: Cognitive function Effetto: None None

Popolazione: Alzheimer's disease patients

Key Statistics

18

Studi

3200

Partecipanti

Positive

B

Grado

Referenced Papers

Newborn (Clarksville, Md.) 2024 9 citazioni
Current opinion in … 2023 58 citazioni
Nutrients 2022 76 citazioni
The Senior care … 2021 2 citazioni
Psychiatrike = Psychiatriki 2020 15 citazioni
Nutricion hospitalaria 2019 40 citazioni
Actas espanolas de … 2017 22 citazioni
European journal of … 2014 204 citazioni
Advances in nutrition … 2013 155 citazioni
Molecular neurobiology 2010 145 citazioni
Journal of Alzheimer's … 2010 110 citazioni
Women's health (London, … 2010 48 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

Limite massimo: 3,000 mg/day combined DHA/EPA (FDA GRAS)

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Mixed 3582
IL triamcinolone every 4 weeks + calcipotriol twice daily 12 weeks Positive 73
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Mixed --
Vitamin D3 vs triamcinolone acetonide 12 weeks Positive 40
None -- Positive --

Momento migliore per l'assunzione: With meals containing fat for better absorption

Safety & Side Effects

Effetti collaterali segnalati

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

Interazioni note

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

Livello di assunzione massimo tollerabile: 3,000 mg/day combined DHA/EPA (FDA GRAS)

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with Mild Cognitive Impairment (MCI)?
Based on 18 studies with 3,200 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support Mild Cognitive Impairment (MCI) management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Mild Cognitive Impairment (MCI)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Mild Cognitive Impairment (MCI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.